Compare GSK Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs SANOFI INDIA - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA SANOFI INDIA GSK PHARMA/
SANOFI INDIA
 
P/E (TTM) x 32.0 38.2 83.7% View Chart
P/BV x 12.7 6.7 190.4% View Chart
Dividend Yield % 1.2 1.3 95.4%  

Financials

 GSK PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
SANOFI INDIA
Dec-18
GSK PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3,5956,840 52.6%   
Low Rs1,2534,630 27.1%   
Sales per share (Unadj.) Rs184.71,203.1 15.3%  
Earnings per share (Unadj.) Rs26.3165.3 15.9%  
Cash flow per share (Unadj.) Rs29.2209.9 13.9%  
Dividends per share (Unadj.) Rs20.0084.00 23.8%  
Dividend yield (eoy) %0.81.5 56.3%  
Book value per share (Unadj.) Rs126.3963.6 13.1%  
Shares outstanding (eoy) m169.4023.03 735.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.14.8 275.4%   
Avg P/E ratio x92.234.7 265.7%  
P/CF ratio (eoy) x83.127.3 304.2%  
Price / Book Value ratio x19.26.0 322.4%  
Dividend payout %76.150.8 149.7%   
Avg Mkt Cap Rs m410,626132,078 310.9%   
No. of employees `0005.03.3 150.3%   
Total wages/salary Rs m5,3724,068 132.1%   
Avg. sales/employee Rs Th6,306.78,393.8 75.1%   
Avg. wages/employee Rs Th1,083.11,232.4 87.9%   
Avg. net profit/employee Rs Th898.01,153.0 77.9%   
INCOME DATA
Net Sales Rs m31,28127,708 112.9%  
Other income Rs m1,023897 114.1%   
Total revenues Rs m32,30428,605 112.9%   
Gross profit Rs m6,0096,235 96.4%  
Depreciation Rs m4861,027 47.3%   
Interest Rs m67 85.7%   
Profit before tax Rs m6,5406,098 107.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,3732,292 103.5%   
Profit after tax Rs m4,4543,806 117.0%  
Gross profit margin %19.222.5 85.4%  
Effective tax rate %36.337.6 96.5%   
Net profit margin %14.213.7 103.7%  
BALANCE SHEET DATA
Current assets Rs m20,06115,922 126.0%   
Current liabilities Rs m14,5436,235 233.3%   
Net working cap to sales %17.635.0 50.5%  
Current ratio x1.42.6 54.0%  
Inventory Days Days5764 89.2%  
Debtors Days Days1421 67.4%  
Net fixed assets Rs m14,3437,539 190.2%   
Share capital Rs m1,694230 736.5%   
"Free" reserves Rs m19,70421,962 89.7%   
Net worth Rs m21,39822,192 96.4%   
Long term debt Rs m20-   
Total assets Rs m39,11329,839 131.1%  
Interest coverage x1,091.0872.1 125.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.9 86.1%   
Return on assets %11.412.8 89.2%  
Return on equity %20.817.2 121.4%  
Return on capital %31.927.5 116.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5347,587 7.0%   
Fx outflow Rs m7,0917,145 99.2%   
Net fx Rs m-6,557442 -1,483.5%   
CASH FLOW
From Operations Rs m3,9943,739 106.8%  
From Investments Rs m-1,433-731 196.1%  
From Financial Activity Rs m-3,584-1,972 181.7%  
Net Cashflow Rs m-1,0231,036 -98.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 60.4 83.9%  
Indian inst/Mut Fund % 10.2 14.4 70.8%  
FIIs % 23.8 14.6 163.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   102,036 15,184 672.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  SUVEN LIFESCIENCES  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Marginally Higher; Healthcare Stocks Witness Buying(09:30 am)

Asian share markets are trading on a negative note today as Japanese and Hong Kong shares show losses. The Nikkei 225 is down 0.79% while the Hang Seng is down 1.73%.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 13, 2019 10:57 AM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - NOVARTIS COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS